

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
INVESTIGATIONAL NEW DRUG (IND) CLEARANCE BY THE
US FDA FOR GT20029 FOR ANDROGENETIC ALOPECIA AND
ACNE VULGARIS**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) to inform the shareholders and potential investors of the Company about the latest business advancement of the Group. Reference is made to the announcement of the Company dated April 15, 2021.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that the Group has received investigational new drug (IND) clearance by the United States Food and Drug Administration (the “**US FDA**”) for GT20029 for the treatment of androgenetic alopecia and acne vulgaris (the “**Clinical Trial**”) in the United States (the “**US**”).

The Clinical Trial is a randomised, double-blind, vehicle-controlled, parallel-group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of GT20029 following topical single and multiple ascending dose administration.

Since the Group’s deployment of Proteolysis Targeting Chimera (“**PROTAC**”) platform in 2018, GT20029, with androgen receptor (“**AR**”) as the target, has been the first compound developed by the Group’s in-house PROTAC platform. To the best of the Directors’ knowledge, GT20029 is the first topical PROTAC compound which entered clinical stage around the world. The phase I clinical trial of GT20029 for the treatment of androgenetic alopecia and acne vulgaris in China has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China in April 2021 and the first subject dosing is expected to be in July 2021.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GT20029 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, July 13, 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*